![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Between January 1985 and May 1988, 87 patients with stage III-IV ovarian carcinoma were entered in a study assessing chemotherapy consisting of cyclophosphamide. 500 mg/m2, epirubicin, 75 mg/m2, and cisplatin, 50 mg/m2, intravenously (IV) on day 1, every 4 weeks (CEP-1). The results after a median follow-up of 4 years are presented. The pathologically complete remission rate was 36%. The median survival of all patients was 26 months. For patients with stage III disease debulked to lesions 1.5 cm before the initiation of chemotherapy (n = 35), the median survival was 61+ months. These data are not clearly different from the results of a previous study conducted by our group utilizing CAP-I chemotherapy.